Mode
Text Size
Log in / Sign up

Clozapine Use Linked to Higher SARS-CoV-2 Infection Risk in Severe Mental DisordersClozapine users faced higher risk of severe COVID-19 in large study

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret clozapine-associated SARS-CoV-2 infection risk cautiously due to high heterogeneity and observational design.

This meta-analysis, systematic review, and retrospective cohort study investigated the association between clozapine use and SARS-CoV-2 infection risk and COVID-19 severity in outpatients with severe mental disorders. The analysis included 155,945 patients, though the specific setting (e.g., geographic location, healthcare system) was not reported. The intervention/exposure was clozapine use, compared to non-users of clozapine (which may include users of other antipsychotics or no antipsychotic medication).

The primary outcome was SARS-CoV-2 infection rate and COVID-19 severity. The main results showed that clozapine users had a higher rate of SARS-CoV-2 infection compared to non-users, with an absolute rate of 18% versus 10% (odds ratio [OR] 1.53, 95% confidence interval [CI]: 1.02-2.30, p = 0.044). This indicates a statistically significant increased risk of infection associated with clozapine use. Additionally, COVID-19 severity was reported to be increased in clozapine users compared to non-users, but no specific effect size, absolute numbers, or confidence intervals were provided for this outcome.

Secondary outcomes were not reported in the available data. Safety and tolerability findings, including adverse events, serious adverse events, discontinuations, and overall tolerability, were also not reported. The study did not provide information on follow-up duration, funding sources, or conflicts of interest.

A key limitation noted is high heterogeneity (I² = 91.2%), which suggests substantial variation in effects across the included studies. This high heterogeneity reduces the reliability of the pooled estimates and indicates that the true effect may differ depending on study characteristics. The authors caution that the findings represent an association, not causation, and that further research is needed to clarify the relationship.

Compared to prior studies, this meta-analysis adds to the evidence base by pooling data from multiple sources, but the high heterogeneity limits direct comparison with landmark trials. Previous research has suggested that clozapine may have immunomodulatory effects, which could theoretically increase susceptibility to infections, but this remains speculative.

Methodological limitations include the lack of reported details on study design, setting, and patient characteristics, which may introduce bias. The retrospective nature of the included cohort studies also raises concerns about confounding by indication (e.g., patients on clozapine may have more severe mental illness or other comorbidities that independently increase infection risk).

Clinically, these findings suggest that clinicians should be vigilant about infection risk in patients with severe mental disorders who are prescribed clozapine, particularly during the COVID-19 pandemic. However, given the observational nature and high heterogeneity, these results should not prompt changes in clozapine prescribing without further evidence. The benefits of clozapine for treatment-resistant schizophrenia must be weighed against potential risks.

Unanswered questions include whether the increased infection risk is specific to clozapine or applies to other antipsychotics, the mechanisms underlying the association, and whether interventions such as vaccination or prophylactic measures can mitigate risk. Future studies should aim to control for confounders and provide more granular data on COVID-19 severity and outcomes.

For people living with severe mental disorders, staying healthy during a pandemic was already a major challenge. Now, a new look at data suggests that taking the medication clozapine might make catching the virus or getting sick from it more likely. This study examined over 155,000 outpatients who were taking clozapine or a different antipsychotic drug. The goal was to see if the medication itself changed how people handled the SARS-CoV-2 virus that causes COVID-19. The results showed a clear difference between those on clozapine and those who were not taking it. People on clozapine had an 18 percent chance of getting infected compared to 10 percent for others. When infection did happen, the illness was often more severe for the clozapine group. The researchers calculated that the risk of infection was about 1.5 times higher for those taking this specific drug. This is a significant increase that cannot be ignored by patients or doctors.

The study looked at many different sources of data to get a broad picture. However, the data came from many different places, which made the results vary a lot. This variation is called heterogeneity and it was very high in this analysis. Because the data was so different from one group to another, it is hard to say exactly why the risk was higher. Some factors like age, other health problems, or how the virus spread in different areas could have played a role. The study found an association between taking clozapine and the increased risk. An association means the two things happened together, but it does not prove that the drug directly caused the infection. It is possible that other factors linked to taking clozapine were responsible for the higher risk.

Safety was not a primary focus of this specific analysis because the main goal was to track infection rates and severity. The study did not report on side effects or how well patients tolerated the medication. This is common in large reviews that focus on specific outcomes like infection. Patients should not stop taking their medication without talking to their doctor. Stopping clozapine suddenly can be dangerous for mental health. The findings highlight a need for more research to understand the link between this drug and viral infections. Until more data is available, doctors must weigh the mental health benefits of clozapine against these potential risks. For many patients, the drug is essential for managing severe mental illness. The increased risk of infection is a concern that needs careful discussion between patients and their care teams.

What does this mean for you right now? If you take clozapine, you are not alone. Many people rely on this medication to live stable lives. The study shows that you might be at higher risk for getting sick or having a harder time fighting it off. This does not mean you should stop taking your medicine. It means you should be extra careful about preventing infection. Wearing masks, washing hands, and avoiding crowds are still important steps. Talk to your doctor about your specific situation. They can help you understand the risks and benefits of your treatment plan. This study adds to the conversation about how mental health medications interact with viral infections. More research is needed to clarify the exact reasons behind these findings. For now, the message is clear: stay safe and keep your doctor informed about your health needs.

What this means for you:
Clozapine users had higher infection risk and severity, but do not stop medication without talking to your doctor.

Study Details

Study typeMeta analysis
Sample sizen = 155,945
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Clozapine's immune-modulating effects, including neutropenia and suppression of adaptive immunity, have raised concerns about its potential impact on SARS-CoV-2 infection risk and COVID-19 severity in individuals with treatment-resistant schizophrenia. Findings in the literature remain inconsistent. METHODS: First, we conducted a longitudinal retrospective study in which we analysed 995 outpatients with severe mental disorders receiving antipsychotic treatment to assess the association between clozapine use and SARS-CoV-2 infection and disease severity. Secondly, we performed a systematic review of the literature and searched for studies published up to July 2025 examining the link between clozapine exposure and SARS-CoV-2 infection. Eight cohort studies plus our dataset were meta-analysed using a random-effects model. RESULTS: In our cohort, clozapine users demonstrated a higher rate of SARS-CoV-2 infection (18% vs. 10%, p < 0.001) and increased COVID-19 severity compared to non-users. The meta-analysis comprised 155,945 participants, with individual study ORs ranging from 0.40 to 2.80. The pooled random-effects OR was 1.53 (95% CI: 1.02-2.30, p = 0.044), indicating a significant association between clozapine exposure and increased infection risk. However, high heterogeneity (I² = 91.2%) suggests variation in effects across studies. CONCLUSIONS: Clozapine treatment is associated with an increased risk and severity of SARS-CoV-2 infection. Although meta-analytic results support this association, substantial heterogeneity in pooled estimates highlights the need for further research to clarify underlying clinical and methodological factors influencing risk.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.